Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies. The safety and efficacy of pomalidomide, low-dose dexamethasone, and daratumumab was evaluated in lenalidom...

Descripción completa

Detalles Bibliográficos
Autores principales: Siegel, David S., Schiller, Gary J., Samaras, Christy, Sebag, Michael, Berdeja, Jesus, Ganguly, Siddhartha, Matous, Jeffrey, Song, Kevin, Seet, Christopher S., Talamo, Giampaolo, Acosta-Rivera, Mirelis, Bar, Michael, Quick, Donald, Anz, Bertrand, Fonseca, Gustavo, Reece, Donna, Pierceall, William E., Chung, Weiyuan, Zafar, Faiza, Agarwal, Amit, Bahlis, Nizar J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685974/
https://www.ncbi.nlm.nih.gov/pubmed/32376855
http://dx.doi.org/10.1038/s41375-020-0813-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685974/
https://www.ncbi.nlm.nih.gov/pubmed/32376855
http://dx.doi.org/10.1038/s41375-020-0813-1

Ejemplares similares